A disease-specific, patient-reported outcome instrument suitable for evaluation of prodromes and attacks of hereditary angioedema (HAE) is a clinical unmet need. We constructed such instrument and examined its validity, acceptability, and discriminative ability. Sixty-six patients participated in a survey addressing their demographics, social, and medical status. Discriminant content validity involved: (1) construct definition by in-depth cognitive debriefing interviews, (2) item selection identifying relevant categories, and (3) judgment of the format whereby questionnaires were tested on experienced patients and its content/reliability was validated. Prodromes and attacks affecting certain body systems (domains) were organized in “clusters”. Internal consistency, content, and convergent validities were analyzed. Analyses of variance and regression models were used to evaluate the discriminative ability of the instrument to differentiate between attacks and prodromes. The study demonstrates very high internal consistency (Cronbach’s α: attacks 0.88–0.98, prodromes 0.78–0.98). Analysis of variance confirmed significant differences between all dimensions and in pre-defined clusters (F (4, 61) = 45.74, p < 0.001, Eta2 = 0.77). Significant correlations were found between dimensions of prodromes and attacks. Prodromes are associated but differentiated from attacks. Correlations in severity were high for all domains. Interactions were found between prodromes and patients' experience in illness. In conclusion, the new Prodrome-Attack Evaluation questionnaire (HAE-EPA) is capable of distinguishing attacks and prodromes of HAE, as well as determining associations between the two interrelated phenomena. The new instrument achieves the required discriminative ability, acceptability, and content validity/reliability and therefore can be used as a reliable tool for the investigation of prodromes, attacks, and their relationships.
This is a preview of subscription content, access via your institution.
We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.
Iris Leibovich Nassi RN, PhD thesis (Tel Aviv University).
Complement 1-esterase Inhibitor
HAE Evaluation of Prodromes and Attacks
Health-related quality of Life
Busse PJ, Christiansen SC (2020) Hereditary angioedema. N Engl J Med 382:1136–1148. https://doi.org/10.1056/NEJMra1808012
Reshef A, Kidon M, Leibovich I (2016) The story of angioedema: from Quincke to bradykinin. Clin Rev Allergy Immunol 51(2):121–139. https://doi.org/10.1007/s12016-016-8553-8
Zuraw BL, Christiansen SC (2016) HAE: pathophysiology and underlying mechanisms. Clin Rev Allergy Immunol 51(2):216–229. https://doi.org/10.1007/s12016-016-8561-8
Kaplan AP, Joseph K (2017) Pathogenesis of hereditary angioedema: the role of the bradykinin-forming cascade. Immunol Allergy Clin N Am 37(3):513–525. https://doi.org/10.1016/j.iac.2017.04.001
Lumry WR, Castaldo AJ, Vernon MK et al (2010) The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression. Allergy Ast Proc 31(5):407–414
Wilson D, Bork K, Shea EP et al (2010) Economic costs associated with acute attacks and long-term management of hereditary angioedema. Ann Allergy, Ast and Immunol 104(4):314–320. https://doi.org/10.1016/j.anai.2010.01.024
Lumry WR (2018) Hereditary angioedema: the economics of treatment of an orphan disease. Front Med 5:22. https://doi.org/10.3389/fmed.2018.00022
Kemp JG, Craig TJ (2009) Variability of prodromal signs and symptoms associated with hereditary angioedema attacks: a literature review. Allergy Ast Proc 30:493–499
Prematta MJ, Kemp JG, Gibbs JG, Craig TJ (2009) Frequency, timing, and type of prodromal symptoms associated with hereditary angioedema attacks. Allergy Ast Proc 30:506–511
Prematta MJ, Bewtra AK, Levy RJ et al (2012) Per-attack reporting of prodromal symptoms concurrent with C1-inhibitor treatment of hereditary angioedema attacks. Adv Ther 29(10):913–922. https://doi.org/10.1007/s12325-012-0053-5
Reshef A, Prematta M, Craig TJ (2013) Signs and symptoms preceding acute attacks of hereditary angioedema: results of three recent surveys. Allergy Ast Proc 34(3):261–266
Leibovich-Nassi I, Golander H, Somech R, Har-Even D, Reshef A (2019) Are HAE patients able to distinguish prodromes from attacks, and are they correlated? Allergy, Ast Clin Immunol 15(Suppl 4):P10
Santana MJ, Feeny D (2014) Framework to assess the effects of using patient-reported outcome measures in chronic care management. Qual Life Res 23:1505–1513
Nelson EC, Eftimovska E, Lind C et al (2015) Patient reported outcome measures in practice. BMJ 350:g7818. https://doi.org/10.1136/bmj.g7818
Kelman L (2004) The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs. Headache 44(9):865–872
Schoonman GG, Evers DJ, Terwindt GM, van Dijk JG, Ferrari MD (2006) The prevalence of premonitory symptoms in migraine: a questionnaire study in 461 patients. Cephalalgia 26:1209–1213
Houtveen JH, Sorbi MJ (2013) Prodromal functioning of migraine patients relative to their interictal state—an ecological momentary assessment study. PLoS ONE 8(8):e72827. https://doi.org/10.1371/journal.pone.0072827
Lidar M, Yaqubov M, Zaks N et al (2006) The prodrome: a prominent yet overlooked pre-attack manifestation of familial Mediterranean fever. J Rheumatol 33(6):1089–1092
Babaoglu H, Varan O, Kucuk H et al (2019) On demand use of anakinra for attacks of familial Mediterranean fever (FMF). Clin Rheumatol 38(2):577–581
Vernon MK, Rentz AM, Wyrwich KW, White MV, Grienenberger A (2009) Psychometric validation of two patient-reported outcome measures to assess symptom severity and changes in symptoms in hereditary angioedema. Qual Life Res 18:929–939. https://doi.org/10.1007/s11136-009-9509-8
McMillan CV, Speight J, Relan A et al (2012) Content validity of visual analog scales to assess symptom severity of acute angioedema attacks in adults with hereditary angioedema: an interview study. Patient 5(2):113–126. https://doi.org/10.2165/11597490-000000000-00000
Weller K, Groffik A, Magerl M et al (2013) Development, validation, and initial results of the Angioedema Activity Score. Allergy 68:1185–1192
Bonner N, Abetz-Webb L, Renault L et al (2015) Development and content validity testing of a patient-reported outcomes questionnaire for the assessment of hereditary angioedema in observational studies. Health Qual Life Outcomes 3:92. https://doi.org/10.1186/s12955-015-0292-7
Bygum A, Busse P, Caballero T et al (2017) Disease severity, activity, impact and control and how to assess them in patients with hereditary angioedema. Front Med 4:212
Weller K, Donoso T, Magerl M et al (2020a) Development of the Angioedema Control Test—a patient-reported outcome measure that assesses disease control in patients with recurrent angioedema. Allergy 75:1165–1177
Weller K, Donoso T, Magerl M et al (2020b) Validation of the Angioedema Control Test (AECT)—a patient reported outcome instrument for assessing angioedema control. J Allergy Clin Immunol Pract 8(6):2050–2057
João Forjaz M, Ayala A, Caminoa M et al (2020) HAE-AS, a specific disease activity scale for hereditary angioedema with C1-inhibitor deficiency. J Investig Allergol Clin Immunol 10. Online ahead of print. https://doi.org/10.18176/jiaci.0479
Weller K, Groffik A, Magerl M et al (2012) Development and construct validation of the angioedema quality of life questionnaire. Allergy 67:1289–1298
Prior N, Remor E, Gomez-Traseira C et al (2012) Development of a disease-specific quality of life questionnaire for adult patients with hereditary angioedema due to C1 inhibitor deficiency (HAE-QoL): Spanish multi-centre research project. Health Qual Life Outcomes 10:82
Weller K, Magerl M, Peveling-Oberhag A et al (2016) The Angioedema Quality of Life Questionnaire (AE-QoL)—assessment of sensitivity to change and minimal clinically important difference. Allergy 71:1203–1209
Prior N, Remor E, Pérez-Fernández E et al (2016) Psychometric field study of Hereditary Angioedema Quality of Life Questionnaire for adults: HAE-QoL. J Allergy Clin Immunol Pract 4:464–473
Strauss AL, Glaser BG (1975) Chronic illness and the quality of life (2nd Edition). Saint-Louis MO: CV Mosby pp160. ISBN-10: 0801648378
Leibovich-Nassi I, Golander H, Somech R, Har-Even D, Reshef A (2019) A new instrument for the evaluation of premonitory signs and symptoms (prodromes) of Hereditary Angioedema. Allergy 74: S106 (P. 215)
Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL (2000) Defining the clinically important difference in pain outcome measures. Pain 88:287–294. https://doi.org/10.1016/s0304-3959(00)00339-0
Cronbach L (1951) Coefficient alpha and the internal structure of tests. Psychometrika 16:297–334
Baiardini I, Bousquet PJ, Brzoza Z et al (2010) Recommendations for assessing patient reported outcomes and health-related quality of life in clinical trials on allergy: a GA(2)LEN taskforce position paper. Allergy 65(3):290–295. https://doi.org/10.1111/j.1398-9995.2009.02263.x
Baiardini I, Braido F, Bindslev-Jensen C et al (2011) Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA(2) LEN taskforce position paper. Allergy 66(7):840–844. https://doi.org/10.1111/j.1398-9995.2011.02580.x
Leibovich-Nassi I, Reshef A, Somech R, Golander H (2017) A survey of hereditary angioedema in Israel. Allergy, Ast Clin Immunol 13(Suppl 2):34
Barlow JH, Cullen A, Rowe IF (1999) Comparison of knowledge and psychological well-being between patients with a short disease duration and patients with more established rheumatoid arthritis. Pat Edu Counsel 38:195–203
Scully JL (2004) What is a disease? Disease, disability and their definitions. Europ Moll Biology Organ Rep 5(7):650–653
Folkman S, Lazarus R (1980) An analysis of coping in a middle-aged community sample. J Health Soc Behav 21:219–239
Lazarus R, Folkman S (1984) Stress. Appraisal and Coping, New York, Springer
Maurer M, Aberer W, Bouillet L et al (2013) Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment. PLoS ONE 8(2):e53773. https://doi.org/10.1371/journal.pone.0053773
Betschel S, Badiou J, Binkley K et al (2019) The International/Canadian Hereditary Angioedema Guideline. Allergy Ast Clin Immunol 15:72. https://doi.org/10.1186/s13223-019-0376-8
Kreiberg KB, Bygum A (2019) Reporting through smartphone application results in detailed data on acquired and hereditary angioedema attacks. Allergy 74:1800–1802
ILN received educational grants from the Stanley Steyer Foundation (Tel Aviv University, Israel) and CSL-Behring (Marburg, Germany).
Conflict of Interest
The authors declare that they have no conflict of interest.
The study was approved and supervised by the Ethics and Helsinki IRB committees of Tel Aviv University, Sheba Medical Center and Barzilai Medical Center, Israel.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Leibovich-Nassi, I., Golander, H., Somech, R. et al. New Instrument for the Evaluation of Prodromes and Attacks of Hereditary Angioedema (HAE-EPA). Clinic Rev Allerg Immunol (2021). https://doi.org/10.1007/s12016-021-08843-8
- Hereditary angioedema